Pharmaceutical Information - December 5, 2008

Lawmakers Still Want OTC Status For Morning-After-Pill

October 11, 2005 - Topics prescription, plan b, pharmaceutical, food and fda
Lawmakers want the new acting head of the Food and Drug Administration to allow sales of Barr Pharmaceuticals Inc's "morning-after" pill without a prescription, according to a letter made public on Tuesday.

Barr has pursued over-the-counter sales of its emergency contraceptive drug, called Plan B, for more than two years

read more >>

Lawmakers Call For OTC Approval For Morning-After-Pill

October 11, 2005 - Topics prescription, plan b, pharmaceutical, food and fda
Lawmakers want the new acting head of the Food and Drug Administration to allow sales of Barr Pharmaceuticals Inc's "morning-after" pill without a prescription, according to a letter made public on Tuesday.

Barr has pursued over-the-counter sales of its emergency contraceptive drug, called Plan B, for more than two years

read more >>

Study: Scientists Pinpoint Inflammation Gene

October 9, 2005 - Topics study, stress, disorder, genetic and disease
A study released Sunday in the online issue of Nature Genetics reveals that a team of international researchers discover that a specific gene on chromosome 15 regulates inflammation, a finding with implications for a wide range of disorders, including cancer, cardiovascular disease, diabetes, obesity, Alzheimer's, and infections.

"Practically every common disease involves an inflammation component," says John Blangero, Ph.D., a scientist at the Southwest Foundation for Biomedical Research in San Antonio and the paper's senior author

read more >>

U.S. Opens HIV/AIDS Hospital In Tanzania

October 9, 2005 - Topics hospital, hiv, aids, africa and pharmaceutical
A $35 million dollar U.S. funded HIV/AIDS treatment center opens at Tanzania's main referral hospital, the Muhimbili National Hospital, with a capacity to process up to 1,000 tests in an hour.

The money comes from funding given to fight HIV/AIDS and TB in poor African countries by the Bush Administration

read more >>

Green Light Given For New Tablets

October 7, 2005 - Topics nutrition, prescription, diabetes, fda and global
The Perrigo Company announced that through a partnership with InvaGen Pharmaceuticals, it has received final approval from the U.S. Food and Drug Administration (FDA) to market Glimepiride Tablets.

Shipment of the product will begin immediately. The product is the generic equivalent to Aventis' Amaryl(R) Tablets, 1 mg, 2 mg and 4 mg, indicated for the treatment of diabetes

read more >>





© Copyright 2008 Webmedia Publishing, SA - all rights reserved.     Contact Us  |  Privacy Policy  |  Disclaimer  |  Terms of Use